Tumor pharmacokinetics of hexamethylmelamine in CDF1 mice bearing P388 leukemia.
The pharmacokinetics and metabolism of hexamethylmelamine (HMM) have been studied in CDF1, mice bearing P388 leukemia. The results obtained for this tumor, which is naturally resistant to HMM, were compared with data on HMM sensitive RC tumor and plasma. The pharmacokinetic parameters, estimated by an original algorithm (FADHA), indicated that HMM Cmax and AUC were very high in RC and P388 tumors as compared to plasma values, but could not be directly correlated with HMM activity. Hydroxymethylpentamethylmelamine (HMPMM), a potentially anticancer metabolite of HMM, was easily detected in P388 leukemia while very poorly detected in RC tissue. This finding led us to make the hypothesis that HMM activity could correlate with HMPMM ability to interact irreversibly with DNA and proteins in tumors.
Dubois
J
J
Université Libre de Bruxelles, Institut de Pharmacie, Belgium.
Atassi
G
G
Hanocq
M
M
Abikhalil
F
F
D006585:Altretamine / Q000493:pharmacokinetics*; D000818:Animals; D001711:Biotransformation; D006900:Hydroxylation; D007941:Leukemia P388 / Q000378:metabolism*; D007942:Leukemia, Experimental / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D014227:Triazines / Q000493:pharmacokinetics*
D014227:Triazines; D006585:Altretamine